New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

Two new moms talk about the special services and care that made giving birth at Providence Little Company of Mary a joyful experience.

​​​​​​​Ion robot-assisted bronchoscopy and Lung Nodule Clinic continue to ease patients’ way

Providence Cancer Institute researcher shares her journey to immunology and the advice she has for those seeking a career in cancer research.

The American College of Radiology (ACR) has once again awarded a three-year term of accreditation to the Providence Cancer Center for its radiation oncology program.

Jennifer Burrows, RN, has been chosen to serve as the chief executive of Providence Oregon.

Dr. Remi Ajiboye recently joined with a new partner, the state-of-the-art ExcelsiusGPS robotic navigation system. Here he talks about how it gives him an edge in patient care.

Carissa Silva has been named the new executive director of Strategy and Business Development for the Providence Alaska region.

Aortic stenosis is a condition in which blood flow out of the heart is obstructed, often leading to shortness of breath, chest pain, fatigue, leg swelling or even heart failure

Delivering state-of-the-art care in brand new NICU

Genetic testing provides insight into inherited health risks.

Sprawling multi-million dollar facility in Orange County is a one-stop location to access full-suite of women’s health, mother-baby services and more

Discover leading-edge approaches for lasting relief.

Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509.

A lifeline for stroke survival.

Considered one of the top hospitals in the nation for the treatment of digestive issues, we bring uncommon expertise to protecting your health and well-being. Here you’ll find the entire range of solu

When the SpaceX mission returns to earth in April, there will be 80 mice onboard who have spent a month living at the International Space Station. The rodents represent the first investigational ophth

Precision technology empowers early detection for improved patient outcomes

Margaret M. Horvath, FACHE, has been named executive director of Providence Alaska Children’s Hospital in Anchorage.

Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.

Following months of planning and approvals, the robotic surgery program at St. Joseph Hospital launched with resounding success on Friday, April 5.

Ion robot-assisted bronchoscopy and Lung Nodule Clinic continue to ease patients’ way